ZB-131 is under clinical development by ZielBio and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ZB-131 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZB-131 overview
ZB-131 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, ovarian cancer, pancreatic ductal adenocarcinoma and metastatic biliary tract cancer including extrahepatic bile duct cancer, gallbladder cancer. It is a humanized monoclonal antibody which acts by targeting cell surface plectin (CSP). The drug candidate is developed based on Zielfind platform. It is administered through intravenous route.
See Also:
ZielBio overview
ZielBio, Inc., is a biotechnology company that identifies high value disease targets and develops therapeutic interventions to improve patient outcomes. The company is headquartered in United States.
For a complete picture of ZB-131’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
